Login / Signup

Hydroxychloroquine and Mortality Among Patients With Systemic Lupus Erythematosus in the General Population.

April M JorgeNatalie McCormickNa LuYufei ZhengJohn EsdaileMary A De VeraHyon K ChoiJuan Antonio Aviña-Zubieta
Published in: Arthritis care & research (2021)
Our general population data support a substantial survival benefit associated with current HCQ use. Increased mortality among patients who had discontinued HCQ recently could be due to a sick stopper effect or the loss of actual HCQ benefits.
Keyphrases
  • cardiovascular events
  • risk factors
  • electronic health record
  • coronary artery disease